Phathom Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
PHAT$5.25+3.3%Stored close · as of Nov 6, 2026
Contents
Balance Sheets
(in thousands, except share and par value amounts)
| December 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $297,263 | $381,393 |
| Prepaid expenses and other current assets | 20,866 | 13,194 |
| Accounts receivable, net | 38,797 | 1,637 |
| Inventory | 3,208 | 1,208 |
| Total current assets | 360,134 | 397,432 |
| Property and equipment, net | 1,476 | 2,146 |
| Operating lease right-of-use assets | 613 | 1,475 |
| Restricted cash | 2,862 | 2,863 |
| Inventory, non-current | 11,540 | 8,234 |
| Other long-term assets | 1,693 | 1,692 |
| Total assets | $378,318 | $413,842 |
| Liabilities and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $10,507 | $12,601 |
| Accrued expenses | 53,232 | 17,197 |
| Accrued interest | 1,711 | 1,146 |
| Operating lease liabilities, current | 501 | 726 |
| Current portion of revenue interest financing liability | 19,777 | 7,111 |
| Total current liabilities | 85,728 | 38,781 |
| Long-term debt, net of discount | 201,409 | 137,842 |
| Revenue interest financing liability | 333,261 | 299,816 |
| Operating lease liabilities | — | 462 |
| Other long-term liabilities | 11,500 | 9,700 |
| Total liabilities | 631,898 | 486,601 |
| Commitments and contingencies (Note 3) | ||
| Stockholders’ deficit: | ||
| Preferred stock, $0.0001 par value; authorized shares — 40,000,000 at December 31, 2024 and December 31, 2023; no shares issued and outstanding at December 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.0001 par value; authorized shares — 400,000,000 at December 31, 2024 and December 31, 2023; issued and outstanding shares — 68,518,238 and 57,970,044 at December 31, 2024 and December 31, 2023, respectively | 6 | 5 |
| Treasury stock — 19 shares at December 31, 2024 and December 31, 2023 | — | — |
| Additional paid-in capital | 1,009,425 | 855,921 |
| Accumulated deficit | (1,263,011) | (928,685) |
| Total stockholders’ deficit | (253,580) | (72,759) |
| Total liabilities and stockholders’ deficit | $378,318 | $413,842 |
See accompanying notes.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.